PMID- 35015028
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20240405
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 63
IP  - 1
DP  - 2022 Jan 3
TI  - Visual Field Sensitivity Prediction Using Optical Coherence Tomography Analysis 
      in Hydroxychloroquine Toxicity.
PG  - 15
LID - 10.1167/iovs.63.1.15 [doi]
LID - 15
AB  - PURPOSE: This study investigates the association between local retina structure 
      and visual function in a cohort with long-term hydroxychloroquine (HCQ) use. 
      METHODS: The study included 84 participants (54 participants without toxicity and 
      30 participants with toxicity) with history of chronic HCQ use (14.5 +/- 7.4 years) 
      who had testing with spectral-domain optical coherence tomography (SD-OCT) 
      imaging and Humphrey 10-2 visual fields. Optical coherence tomography (OCT) 
      metrics (total and outer retina thickness [TRT and ORT], minimum intensity 
      [MinI], and ellipsoid zone [EZ] loss) were sampled in regions corresponding to 
      visual field test locations. Univariate linear correlations were investigated and 
      a multivariate random forest regression using a combination of OCT metrics was 
      used to predict visual field sensitivity by locus using a leave-one-out 
      cross-validation strategy. RESULTS: In univariate linear regression, EZ loss 
      demonstrated the strongest relationship with visual field sensitivities in the 
      parafoveal ring with R2 = 0.58. TRT and ORT revealed positive correlations with 
      visual field sensitivity (R2 = 0.57 and 0.40, respectively), whereas total and 
      outer retinal MinI yielded negative correlations (R2 = 0.10 and 0.22). The 
      multivariate model improved correlations (R2 = 0.66) yielding a root mean squared 
      error of 3.8 decibel (dB). Feature importance analysis identified EZ loss as the 
      most relevant predictor of function. CONCLUSIONS: Multiple OCT-derived 
      quantitative metrics used in combination can provide information to predict local 
      sensitivities. The results indicate a strong relationship between retinal 
      function and OCT measures, which contribute to the understanding of the retinal 
      toxicity caused by HCQ as well as being applicable to outcome development for 
      other degenerative diseases of the outer retina.
FAU - Jayakar, Gopal
AU  - Jayakar G
AD  - Unit on Clinical Investigation of Retinal Disease, Division of Epidemiology & 
      Clinical Applications, National Eye Institute, National Institutes of Health, 
      Bethesda, Maryland, United States.
FAU - De Silva, Tharindu
AU  - De Silva T
AD  - Unit on Clinical Investigation of Retinal Disease, Division of Epidemiology & 
      Clinical Applications, National Eye Institute, National Institutes of Health, 
      Bethesda, Maryland, United States.
FAU - Cukras, Catherine A
AU  - Cukras CA
AD  - Unit on Clinical Investigation of Retinal Disease, Division of Epidemiology & 
      Clinical Applications, National Eye Institute, National Institutes of Health, 
      Bethesda, Maryland, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Antirheumatic Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Aged
MH  - Antirheumatic Agents/adverse effects
MH  - Electroretinography
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retinal Diseases/*chemically induced/diagnosis/physiopathology
MH  - Tomography, Optical Coherence/*methods
MH  - *Visual Acuity
MH  - Visual Field Tests
MH  - Visual Fields/*drug effects
PMC - PMC8762675
COIS- Disclosure: G. Jayakar, None; T. De Silva, None; C.A. Cukras, None
EDAT- 2022/01/12 06:00
MHDA- 2022/02/19 06:00
PMCR- 2022/01/11
CRDT- 2022/01/11 12:24
PHST- 2022/01/11 12:24 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2022/01/11 00:00 [pmc-release]
AID - 2778248 [pii]
AID - IOVS-21-33057 [pii]
AID - 10.1167/iovs.63.1.15 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):15. doi: 10.1167/iovs.63.1.15.